Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Passes Below 200-Day Moving Average - Should You Sell?

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.27 and traded as low as $0.18. Northwest Biotherapeutics shares last traded at $0.19, with a volume of 3,818,583 shares traded.

Northwest Biotherapeutics Stock Down 12.4 %

The stock has a 50-day simple moving average of $0.24 and a two-hundred day simple moving average of $0.27. The firm has a market cap of $296.22 million, a PE ratio of -2.66 and a beta of -0.67.

Northwest Biotherapeutics (OTCMKTS:NWBO - Get Free Report) last released its earnings results on Monday, March 31st. The biotechnology company reported ($0.02) earnings per share for the quarter. The company had revenue of $0.23 million during the quarter.

Northwest Biotherapeutics Company Profile

Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.